Gyre Therapeutics Shares Owned By Insiders vs. EBITDA
| GYRE Stock | 12.51 0.81 6.92% |
For Gyre Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Gyre Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Gyre Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Gyre Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Gyre Therapeutics over time as well as its relative position and ranking within its peers.
Gyre |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gyre Therapeutics. If investors know Gyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.04) | Revenue Per Share 1.464 | Quarterly Revenue Growth (0.14) | Return On Assets 0.1018 |
The market value of Gyre Therapeutics is measured differently than its book value, which is the value of Gyre that is recorded on the company's balance sheet. Investors also form their own opinion of Gyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gyre Therapeutics' market value can be influenced by many factors that don't directly affect Gyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Gyre Therapeutics EBITDA vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Gyre Therapeutics's current stock value. Our valuation model uses many indicators to compare Gyre Therapeutics value to that of its competitors to determine the firm's financial worth. Gyre Therapeutics is one of the top stocks in shares owned by insiders category among its peers. It also is one of the top stocks in ebitda category among its peers totaling about 272,101 of EBITDA per Shares Owned By Insiders. At present, Gyre Therapeutics' EBITDA is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Gyre Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Gyre EBITDA vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Gyre Therapeutics |
| = | 74.70 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Gyre Therapeutics |
| = | 20.33 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Gyre EBITDA Comparison
Gyre Therapeutics is currently under evaluation in ebitda category among its peers.
Gyre Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Gyre Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Gyre Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Gyre Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Gyre Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.5 M | 1.5 M | |
| Operating Income | -67.2 M | -63.9 M | |
| Net Loss | -85.5 M | -81.2 M | |
| Income Tax Expense | 8.5 M | 8.9 M | |
| Income Before Tax | -77 M | -80.8 M | |
| Total Other Income Expense Net | -9.7 M | -9.2 M | |
| Net Interest Income | 1 M | 744.3 K | |
| Interest Income | 5.6 M | 2.9 M | |
| Net Loss | -85.5 M | -81.2 M | |
| Net Loss | (1.41) | (1.48) | |
| Income Quality | (0.30) | (0.29) | |
| Net Income Per E B T | 1.21 | 1.27 |
Gyre Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Gyre Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Gyre Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Gyre Therapeutics' important profitability drivers and their relationship over time.
Use Gyre Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Gyre Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gyre Therapeutics will appreciate offsetting losses from the drop in the long position's value.Gyre Therapeutics Pair Trading
Gyre Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Gyre Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Gyre Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Gyre Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Gyre Therapeutics to buy it.
The correlation of Gyre Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Gyre Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Gyre Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Gyre Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Gyre Therapeutics position
In addition to having Gyre Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Fabricated Products Thematic Idea Now
Fabricated Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Fabricated Products theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Fabricated Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
To fully project Gyre Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Gyre Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Gyre Therapeutics' income statement, its balance sheet, and the statement of cash flows.